Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.

Animals Cell Cycle Proteins / antagonists & inhibitors HEK293 Cells HeLa Cells Humans Molecular Docking Simulation Molecular Structure Peptides, Cyclic / chemical synthesis Peptidomimetics / chemical synthesis Protein Binding Protein Domains Protein Kinase Inhibitors / chemical synthesis Protein Serine-Threonine Kinases / antagonists & inhibitors Proto-Oncogene Proteins / antagonists & inhibitors Structure-Activity Relationship Zebrafish Polo-Like Kinase 1

Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
10 02 2022
Historique:
pubmed: 15 1 2022
medline: 23 2 2022
entrez: 14 1 2022
Statut: ppublish

Résumé

The polo-box domain (PBD) of Plk1 is a promising target for cancer therapeutics. We designed and synthesized novel phosphorylated macrocyclic peptidomimetics targeting PBD based on acyclic phosphopeptide PMQSpTPL. The inhibitory activities of

Identifiants

DOI: 10.1021/acs.jmedchem.1c01359 PMID: 35029981 PMC: PMC10411393
pubmed: 35029981
doi: 10.1021/acs.jmedchem.1c01359
pmc: PMC10411393
mid: NIHMS1917421
doi:

Substances chimiques

Cell Cycle Proteins 0
Peptides, Cyclic 0
Peptidomimetics 0
Protein Kinase Inhibitors 0
Proto-Oncogene Proteins 0
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1915-1932

Subventions

Organisme : NIEHS NIH HHS
ID : R35 ES028374
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC010681
Pays : United States

Références

Bioorg Chem. 2019 Apr;85:534-540
pubmed: 30807896
J Biol Chem. 2002 Aug 30;277(35):32282-93
pubmed: 12034729
Org Biomol Chem. 2015 Apr 21;13(15):4374-94
pubmed: 25768201
Eur J Med Chem. 2016 Nov 29;124:229-236
pubmed: 27592392
Science. 2003 Feb 21;299(5610):1228-31
pubmed: 12595692
Transl Oncol. 2015 Jun;8(3):185-95
pubmed: 26055176
PLoS One. 2009;4(2):e4361
pubmed: 19194508
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
pubmed: 15299374
Nat Rev Cancer. 2006 Apr;6(4):321-30
pubmed: 16557283
J Struct Biol. 1999 Apr-May;125(2-3):156-65
pubmed: 10222271
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3445-54
pubmed: 23946421
Anal Biochem. 2008 Dec 15;383(2):205-9
pubmed: 18793607
J Org Chem. 2016 Jun 3;81(11):4464-74
pubmed: 27149197
J Med Chem. 2020 Nov 25;63(22):14087-14117
pubmed: 33175530
J Med Chem. 2020 Dec 10;63(23):14905-14920
pubmed: 33142063
J Exp Zool B Mol Dev Evol. 2011 Jan 15;316(1):76-92
pubmed: 21154526
Nat Rev Drug Discov. 2005 Jan;4(1):35-44
pubmed: 15688071
Acta Crystallogr D Biol Crystallogr. 1999 Feb;55(Pt 2):484-91
pubmed: 10089360
Nucl Med Biol. 2012 Nov;39(8):1202-12
pubmed: 22784382
Org Lett. 2010 Apr 2;12(7):1552-5
pubmed: 20192259
Nat Rev Drug Discov. 2010 Aug;9(8):643-60
pubmed: 20671765
Cell. 2003 Oct 3;115(1):83-95
pubmed: 14532005
Cell Cycle. 2004 Feb;3(2):128-31
pubmed: 14712072
Dev Reprod. 2014 Mar;18(1):65-71
pubmed: 25949173
J Med Chem. 2015 Jan 8;58(1):294-304
pubmed: 25347203
Nat Rev Mol Cell Biol. 2004 Jun;5(6):429-40
pubmed: 15173822
Chem Biol. 2008 May;15(5):459-66
pubmed: 18482698
Pharmazie. 2002 Jan;57(1):5-29
pubmed: 11836932
Nat Rev Cancer. 2007 Feb;7(2):107-17
pubmed: 17251917
Bioorg Med Chem. 2013 May 1;21(9):2623-34
pubmed: 23498919
Bioorg Chem. 2018 Dec;81:278-288
pubmed: 30170276
Nat Rev Drug Discov. 2009 Jul;8(7):547-66
pubmed: 19568282
Dev Dyn. 1995 Jul;203(3):253-310
pubmed: 8589427
Bioorg Med Chem Lett. 2018 Oct 15;28(19):3202-3205
pubmed: 30174151
Chem Biol Drug Des. 2006 Oct;68(4):213-9
pubmed: 17105485
Nat Chem. 2011 Jun 23;3(7):509-24
pubmed: 21697871
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4849-57
pubmed: 24277814
Mol Cell Biol. 2007 Aug;27(16):5887-97
pubmed: 17576815
Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13194-9
pubmed: 16150706
Mol Cells. 2014 Apr;37(4):286-94
pubmed: 24722413
Dev Biol. 2010 Sep 1;345(1):34-48
pubmed: 20553902
PLoS One. 2014 Sep 11;9(9):e107432
pubmed: 25211362
Acta Crystallogr D Biol Crystallogr. 2006 Aug;62(Pt 8):859-66
pubmed: 16855301
ACS Med Chem Lett. 2010;1(3):110-114
pubmed: 20625469
Chembiochem. 2009 May 4;10(7):1145-8
pubmed: 19350612
J Med Chem. 2020 Feb 27;63(4):1576-1596
pubmed: 32003991
EMBO J. 2003 Nov 3;22(21):5757-68
pubmed: 14592974
Biopolymers. 2014 Nov;102(6):444-55
pubmed: 25283071
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Biopolymers. 2009;92(6):479-88
pubmed: 19521975
Mol Cell. 2006 Nov 3;24(3):409-22
pubmed: 17081991
J Biol Chem. 2009 Jan 23;284(4):2344-53
pubmed: 19033445
J Med Chem. 2021 Jul 22;64(14):9916-9925
pubmed: 34210138
Nat Chem Biol. 2011 Jul 17;7(9):595-601
pubmed: 21765407
Chromosoma. 1997 Nov;106(6):348-60
pubmed: 9362543
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3107-12
pubmed: 17307877
Nat Struct Mol Biol. 2009 Aug;16(8):876-82
pubmed: 19597481
Biochim Biophys Acta. 2009 Oct;1793(10):1571-8
pubmed: 19631697
Nat Rev Mol Cell Biol. 2009 Apr;10(4):265-75
pubmed: 19305416
Anal Biochem. 2009 Dec 15;395(2):189-94
pubmed: 19716361

Auteurs

SeongShick Ryu (S)

KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
Chemical Kinomics Research Center, Korea Institute of Science and Technology, 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.
Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.

Jung-Eun Park (JE)

Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.

Young Jin Ham (YJ)

Chemical Kinomics Research Center, Korea Institute of Science and Technology, 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.

Daniel C Lim (DC)

Koch Institute for Integrative Cancer Research, and Center for Precision Cancer Medicine, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts 02139, United States.

Nicholas P Kwiatkowski (NP)

Harvard Medical School, 25 Shattuck Street, Boston, Massachusetts 02115, United States.
Department of Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, United States.

Do-Hee Kim (DH)

Chemical Kinomics Research Center, Korea Institute of Science and Technology, 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.
Department of Chemistry, College of Convergence and Integrated Science, Kyonggi University, 154 Gwanggyosan-ro, Yeongtong-gu, Suwon 16227, Republic of Korea.

Debabrata Bhunia (D)

Chemical Kinomics Research Center, Korea Institute of Science and Technology, 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.

Nam Doo Kim (ND)

Voronoibio Inc., 32 Songdogwahak-ro, Yeonsu-gu, Incheon 21984, Republic of Korea.

Michael B Yaffe (MB)

Koch Institute for Integrative Cancer Research, and Center for Precision Cancer Medicine, Massachusetts Institute of Technology, 500 Main Street, Cambridge, Massachusetts 02139, United States.
Divisions of Acute Care Surgery, Trauma, and Surgical Critical Care, and Surgical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, United States.

Woolim Son (W)

Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.

Namkyoung Kim (N)

KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
Chemical Kinomics Research Center, Korea Institute of Science and Technology, 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.
Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.

Tae-Ik Choi (TI)

Department of Biology, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea.

Puspanjali Swain (P)

Department of Biology, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea.

Cheol-Hee Kim (CH)

Department of Biology, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea.

Jin-Young Lee (JY)

Department of Biological Sciences, Keimyung University, 1095 Dalgubeol-daero, Dalseo-gu, Daegu 42601, Republic of Korea.

Nathanael S Gray (NS)

Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, Stanford School of Medicine, Stanford University, 290 Jane Stanford Way, Stanford, California 94305, United States.
ORCID: 0000-0001-5354-7403

Kyung S Lee (KS)

Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States.
ORCID: 0000-0001-8326-7162

Taebo Sim (T)

KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
Chemical Kinomics Research Center, Korea Institute of Science and Technology, 5 Hwarangro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.
Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
ORCID: 0000-0003-3015-2059

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cycle cellulaire › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HeLa › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Simulation numérique › Simulation de docking moléculaire › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Peptides cycliques › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Peptidomimétiques › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Structure tertiaire des protéines › Domaines protéiques › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Novel Macrocyclic Peptidomimetics Targeting...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Poissons › Cypriniformes › Cyprinidae › Danio zébré › Novel Macrocyclic Peptidomimetics Targeting...